Cardiol Therapeutics Inc. (TSX:CRDL)
Canada
· Delayed Price · Currency is CAD 1.730
-0.140 (-7.49%)
Feb 21, 2025, 4:00 PM EST
Cardiol Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
141.17M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Thumb Industries | 1.51B |
| dentalcorp Holdings | 1.51B |
| WELL Health Technologies | 957.69M |
| Curaleaf Holdings | 1.83B |
| Sienna Senior Living | 893.16M |
| Trulieve Cannabis | 1.58B |
| Cronos Group | 150.26M |
| Extendicare | 1.42B |
Cardiol Therapeutics News
- 2 days ago - Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure - Newsfile Corp
- 4 days ago - Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts - Seeking Alpha
- 18 days ago - Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Newsfile Corp
- 2 months ago - PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - GlobeNewsWire
- 3 months ago - CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study - Benzinga
- 3 months ago - Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 - Newsfile Corp
- 3 months ago - Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index - GlobeNewsWire
- 4 months ago - IRW-News: Cardiol Therapeutics Inc. : Cardiol Therapeutics will CardiolRx in eine Studie der späten Phase an Patienten mit rezidivierender Perikarditis überführen - Onvista